Could a common Parkinson's drug help treat wet AMD?

NCT ID NCT03023059

Completed Disease control Sponsor: Snyder, Robert W., M.D., Ph.D., P.C. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tested carbidopa-levodopa, a drug used for Parkinson's disease, in 35 people with wet age-related macular degeneration (AMD). The goal was to see if the drug could improve vision and reduce the need for standard anti-VEGF eye injections. Participants took the oral medication alongside their usual injections, and researchers measured changes in vision and retinal thickness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: carbidopa-levodopa (Sinemet)
What this could lead to: If it works, this could reduce the number of anti-VEGF injections needed for wet AMD, making treatment easier for patients.
What could go wrong: This is a small, early-phase trial with only 35 participants. The drug may not improve vision or reduce injections, and side effects like nausea or dizziness are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGE-RELATED MACULAR DEGENERATION

Contacts and locations

Locations

Robert W Snyder, MD, PhD, PC

Tucson, Arizona, 85712, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.